Overview

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)

Status:
Recruiting

Trial end date:
2024-06-27

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo, Inc.

Collaborator:

AstraZeneca

Treatments:

Docetaxel